摘要
10%～15%的非酒精性脂肪性肝炎（NASH）可进展为肝硬化。NASH的发病机制尚未完全阐明,但“二次打击”假设已被普遍接受。目前NASH的药物治疗主要是针对其发病机制。用于治疗NASH的药物很多,包括改善胰岛素抵抗的药物、抗氧化剂、减肥药、熊去氧胆酸、他汀类制剂、血管紧张素受体阻滞剂、壳聚糖等。本文对近年有关NASH药物治疗的研究和荟萃分析结果作一循证评价。
Ten to fifteen percent of patients with nonalcoholic steatohepatitis （NASH） would progress to liver cirrhosis. The pathogenesis of NASH has not been fully elucidated, but the ＂two-hit＂ hypothesis is widely accepted. Drug therapy of NASH is directed against the pathogenesis. A number of drugs have been used in the treatment of NASH, such as insulin resistance improving agents, antioxidant agents, weight-reducing agents, ursodeoxycholic acid, statins, angiotensin receptor blocker and chitosan. This review discussed the evidence-based results of studies and meta-analyses of drug therapy of NASH in recent years.
出处
《胃肠病学》
2009年第1期47-50,共4页
Chinese Journal of Gastroenterology
关键词
非酒精性脂肪性肝炎
药物疗法
循证医学
治疗结果
安全
Nonalcoholic Steatohepatitis
Drug Therapy
Evidence-Based Medicine
Treatment Outcome
Safety
